Wall Street Zen upgraded shares of Coherus Oncology from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Weiss Ratings reiterated a “sell (d)” rating on shares of Coherus Oncology in a research report on Wednesday, October 8th. Get Coherus Oncology alerts:Get Our Latest Stock Analysis on Coherus OncologyCoherus Oncology Price PerformanceShares of NASDAQ CHRS opened at $2.21 on Thursday. Coherus Oncology Company Profile(Get Free Report)Coherus Oncology, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacturing and commercialization of biologic therapies for oncology support and immuno-oncology. See AlsoReceive News & Ratings for Coherus Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Oncology and related companies with MarketBeat.com's FREE daily email newsletter.